FF 10850
Small Cell Lung Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.Small moleculePhase 3Active
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 65/ 100
Competitive context
108 Active assets in the Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 4 | BB |
Irinotecan Sichuan University | Phase 4 | BB |
ETOPOSIDE Sichuan University | Phase 4 | BB |
Hycamtin AbbVie | Phase 4 | BB |
Carboplatin University of Maryland, Baltimore | Phase 4 | BB |
View all 50 →
Same molecule, other indications
FF 10850 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →